Group 1: BeiGene Overview - BeiGene, Ltd. (BGNE) shares increased by 5.3% to close at $246.04, with a notable trading volume compared to normal sessions, and a total gain of 22% over the past four weeks [1] - The rise in stock price is linked to positive investor sentiment regarding BeiGene's marketed drug portfolio, which includes three approved medicines: Brukinsa, Tevimbra, and Partruvix, along with a robust pipeline of investigational candidates [1] - The company is projected to report a quarterly loss of $0.94 per share, reflecting a year-over-year decline of 146.8%, while revenues are expected to reach $976.82 million, marking a 25% increase from the previous year [1] Group 2: Earnings and Stock Performance - Trends in earnings estimate revisions are correlated with near-term stock price movements, and BeiGene's consensus EPS estimate has remained unchanged over the last 30 days [2] - The stock's price typically does not continue to rise without trends in earnings estimate revisions, indicating the need to monitor BGNE for potential future strength [2] - BeiGene holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [2] Group 3: Industry Comparison - BeiGene is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Foghorn Therapeutics Inc. (FHTX), which saw a 4.7% increase to $7.83 but has returned -7.4% over the past month [2] - Foghorn Therapeutics has a consensus EPS estimate that has changed by +2.5% to -$0.42, representing a 23.5% decline from the previous year [3] - Foghorn Therapeutics also holds a Zacks Rank of 3 (Hold), similar to BeiGene [3]

Financial Reporting - BeiGene, Ltd. filed its 2024 Interim Report for the six months ended June 30, 2024, with the STAR Market of the Shanghai Stock Exchange[3] - The STAR Interim Report includes financial information prepared in accordance with PRC GAAP, which differs from U.S. GAAP[4] - The report contains additional financial data for the Reporting Period, including research and development expenses allocated by key products[4] - The financial information regarding research and development expenses is attached as Exhibit 99.1 to the Current Report[4] - The report was signed by Chan Lee, Senior Vice President and General Counsel of BeiGene, Ltd.[8] Availability - The STAR Interim Report is available in Chinese on the Shanghai Stock Exchange's website[5]

分组1 - BeiGene, Ltd. (BGNE) shares have increased by 28.8% over the past four weeks, closing at $202.17, with a mean price target of $258.45 indicating a potential upside of 27.8% [1] - The mean estimate consists of 11 short-term price targets with a standard deviation of $55.54, suggesting variability in analyst predictions; the lowest estimate is $152 (24.8% decline), while the highest is $345 (70.7% increase) [1] - Analysts show strong agreement on BGNE's earnings prospects, with a 32.2% increase in the Zacks Consensus Estimate for the current year, indicating positive revisions without any negative adjustments [5][6] 分组2 - The consensus price target is often viewed with skepticism, as analysts may set overly optimistic targets due to business incentives, which can mislead investors [3][4] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement, serving as a starting point for further research [4] - BGNE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting strong potential for upside [6]

Core Viewpoint - BeiGene, Ltd. (BGNE) is showing potential for a bullish breakout as it has reached a key support level and experienced a "golden cross" in its moving averages [1] Technical Analysis - BGNE's 50-day simple moving average has crossed above its 200-day simple moving average, indicating a bullish signal known as a "golden cross" [1] - A golden cross typically suggests a bullish breakout is likely, formed when a stock's short-term moving average surpasses a longer-term moving average [1] - The three stages of a golden cross include a downtrend that bottoms out, the crossover of moving averages, and continued upward momentum [1] - The occurrence of a golden cross contrasts with a "death cross," which signals potential bearish movement [1] Performance Metrics - BGNE has experienced a rally of 19.3% over the past four weeks, indicating strong upward momentum [1] - The company currently holds a 2 (Buy) rating on the Zacks Rank, further supporting the bullish outlook [1] Earnings Outlook - The positive earnings outlook for BGNE strengthens the bullish case, as no earnings estimates have been cut for the current quarter [1]

Group 1: Stock Performance and Price Targets - Shares of BeiGene, Ltd. (BGNE) have increased by 20.1% over the past four weeks, closing at $182.76, with a mean price target of $257.41 indicating a potential upside of 40.9% [1] - The mean estimate consists of 11 short-term price targets with a standard deviation of $56.75, suggesting variability in analyst predictions; the lowest estimate is $161 (11.9% decline), while the highest is $345 (88.8% increase) [1] Group 2: Analyst Sentiment and Earnings Estimates - There is strong agreement among analysts regarding BeiGene's ability to report better earnings, with five estimates revised higher in the last 30 days and no negative revisions, leading to a 39.2% increase in the Zacks Consensus Estimate [5] - The company currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [6] Group 3: Price Target Reliability - Analysts' price targets can often mislead investors, as empirical research indicates that they rarely predict actual stock price movements accurately [3] - A low standard deviation in price targets indicates a high degree of agreement among analysts, which can serve as a starting point for further research into fundamental drivers [4]

Investment Rating - The report maintains a "Buy" rating for BeiGene, with a target price adjustment from $269.73 to $288.93 [2][18]. Core Insights - BeiGene's product sales exceeded expectations, recording $921 million in Q2 2024, representing a 23% quarter-over-quarter growth and a 66% year-over-year increase [1][2]. - The company achieved non-GAAP profitability, with a significant reduction in net loss to $120 million in Q2 2024 from $251 million in Q1 2024 [2][3]. - Strong sales momentum for Zanubrutinib (Zanu) was noted, with Q2 sales reaching $637 million, a 30% increase quarter-over-quarter and a 107% increase year-over-year [1][2]. Financial Performance - Total product sales for the first half of 2024 reached $1.67 billion, accounting for 51.4% of the previously estimated total for fiscal year 2024 [1][2]. - The gross profit margin increased to 85.0% in Q2 2024 from 83.3% in Q1 2024, driven by a higher proportion of high-margin sales [2][3]. - The SG&A ratio decreased to 48% in Q2 2024 from 57% in Q1 2024, indicating improved operational efficiency [2][3]. Market Position and Growth Potential - Zanu captured approximately 24% of the global BTK inhibitor market in Q2 2024, up from 20% in Q1 2024, with expectations to reach $2.6 billion in sales for FY24, a 102% year-over-year increase [2][3]. - The report highlights the potential of upcoming clinical trials for Sonrotoclax and BGB-16673, which are expected to drive future growth [2][3]. Future Projections - The company is projected to achieve breakeven in FY25E, supported by strong sales growth and improving operating margins [2][3]. - Revenue estimates for FY24E, FY25E, and FY26E are $3.87 billion, $5.49 billion, and $6.99 billion, respectively, with a focus on continued product sales growth [3][12].

Investment Rating - Maintain BUY rating for BeiGene, reflecting strong product growth momentum and near-term profitability [1][2][9] Core Insights - BeiGene's product sales in 2Q24 reached US$921 million, a 23% increase quarter-over-quarter and a 66% increase year-over-year, exceeding expectations [1] - The company achieved non-GAAP profitability with a net loss narrowed to US$120 million in 2Q24, compared to US$251 million in 1Q24, marking a significant milestone [1] - Forecasts indicate that BeiGene's zanubrutinib (zanu) will generate US$2.6 billion in sales for FY24, representing a 102% year-over-year increase, with peak sales projected at US$5.6 billion by 2031 [1] Summary by Sections Sales Performance - Total product sales for 1H24 reached US$1.67 billion, representing 51.4% of the previous FY24 estimate [1] - Zanubrutinib sales increased by 30% quarter-over-quarter and 107% year-over-year to US$637 million, capturing approximately 24% of the global BTK inhibitor market [1][2] Profitability Metrics - Gross profit margin improved to 85.0% in 2Q24 from 83.3% in 1Q24, driven by high-margin product sales and economies of scale [1] - The SG&A ratio decreased to 48% in 2Q24 from 57% in 1Q24, while the R&D ratio shrank to 49% from 62% in the previous quarter [1] Future Growth Potential - The company is advancing clinical trials for sonrotoclax and BGB-16673, which are expected to become future blockbusters [1] - Phase 3 trials for sonrotoclax in R/R CLL and R/R MCL are anticipated to start in late 2024 and early 2025, respectively [1] Financial Projections - Revenue projections for FY24E are set at US$3.87 billion, with net profit expected to turn positive in FY25E at US$53.4 million [2][10] - Target price raised from US$269.73 to US$288.93, indicating a potential upside of 57.9% from the current price of US$183.03 [2][9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37686 BE ...

The speed of growth of a given stock is much higher the smaller it is. Stock size is classified by market capitalization – current share price x number of shares outstanding – with large cap shares being above $10 billion. Generally speaking, once a stock reaches large cap status its growth prospects decline substantially.Thus, it’s generally unreasonable to anticipate 50% returns over a year when it comes to large cap stocks. And while it may be generally unreasonable, it is not impossible.Each of the larg ...

BeiGene, Ltd. (BGNE) is a next-gen oncology company focusing on discovering and developing innovative and affordable treatments for cancer patients worldwide.The company currently markets three internally discovered oncology products, including BTK inhibitor, Brukinsa (zanubrutinib), in the United States, China, the EU, the United Kingdom and additional international markets. BeiGene markets its other products like anti-PD-1 antibody, tislelizumab, in the EU and China, and PARP inhibitor, pamiparib, only in ...